Investigators from Mass General Brigham have developed a way to promote antitumor immunity by hijacking cellular machinery within cancer cells.

Investigators from Mass General Brigham have developed a way to promote antitumor immunity by hijacking cellular machinery within cancer cells. The ...

Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced ...

OCALA, Fla., Nov. 03, 2025 (NYSE American: AIM) ("AIM" or the "Company") today announced that the European Patent Office has officially granted AIM's European Patent No. 4,096,675, titled "Composition ...

The chronic progressive multiple sclerosis market size is anticipated to grow during the forecast period (2025–2034).

Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that data from the ongoing Phase 1b study of R2891, a potent and ...

By stimulating cancer cells to produce a molecule that activates a signaling pathway in nearby immune cells, MIT researchers have found a way to force tumors to trigger their own destruction.

A longevity expert reveals how immune systems begin aging after 35, making people more susceptible to infections and immune-related disorders over time.

In both Ayurveda and naturopathy, winter is seen as a period of renewal. It is an opportunity to rebuild inner strength, ...

New research that sheds light on how the immune system responds to serious eye infections is underway at Wayne State ...

AIM ImmunoTech Inc. (NYSE American: AIM) ('AIM” or the 'Company”) today announced that the European Patent Office has officially granted AIM’s European Patent No. 4,096,675, titled 'Compositions for ...